Overview
U.S. neuroscience drugmaker's Q4 revenue beat analyst expectations despite year-over-year decline
Q4 basic EPS loss was narrower than analysts expected
Outlook
BioXcel Therapeutics continues to progress its Alzheimer's dementia program as part of broader strategy
Result Drivers
CLINICAL TRIAL SPENDING - Increased R&D expenses driven by SERENITY At-Home pivotal Phase 3 safety trial
LOWER SG&A COSTS - SG&A expenses declined due to reduced personnel, legal, and commercial costs from clinical reprioritization
Company press release: ID:nGNX18M597
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $256,000 | $162,000 (5 Analysts) |
Q4 Net Income | Beat | -$12.55 mln | -$14.42 mln (4 Analysts) |
Q4 Basic EPS | Beat | -$0.58 | -$0.75 (4 Analysts) |
Q4 Operating Income | Beat | -$10.28 mln | -$11.70 mln (5 Analysts) |
Q4 Operating Expenses | $10.54 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $12.00, about 775.9% above its March 26 closing price of $1.37
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)